| Preview | Issue Date | Title / Name | Author(s) | Type |
 | May-2024 | 233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC) | Wong, V.; Baron-Hay, Sally; De Boer, R.H.; Boyle, F.; Collins, Ian M., et al | Conference Paper | |
 | May-2024 | 233P: Real world first-line treatment selection for Australian patients with hormone receptor positive advanced breast cancer | Wong, Vanessa; Baron-Hay, Sally; de Boer, Richard; Boyle, F.; Collins, Ian M., et al | Conference Poster | |
| 2022 | CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort | Javaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, F., et al | Conference Paper | |
| 31-May-2023 | Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry. | Wen Lok, Sheau; Tung, Iris; Anton, Angelyn; Baron-Hay, Sally; De Boer, Richard H., et al | Conference Paper | |
| 30-Jul-2026 | Real-world outcomes in patients with hormone receptor positive, human epidermal growth factor receptor 2 receptor-negative advanced breast cancer and visceral metastases at baseline – advanced hormone receptor positive breast cancer registry in Australia | Wigston, Lucas; Morris, Ali; Wen Lok, Sheau; Baron-Hay, Sally; de Boer, Richard, et al | Journal Article | |
| 2015 | Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC). | Khasraw, Mustafa; Mukaro, Violet; West, Linda; Brandt, Conrad; Woollett, Anne Maree, et al | Conference Paper | |
| 2014 | Tailored neoadjuvant epirubicin and cyclophosphamide and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer | Khasraw, Mustafa; West, Linda; Duan, Wei; Mukaro, Violet; Harvey, Sandra, et al | Conference Paper | |
 | 2019 | Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response | Murphy, Caitlin; Muscat, Andrea; Ashley, D.; Mukaro, Violet; West, Linda, et al | Journal Article | |
